'OLAP' (OLAparib regulatory Post-marketing surveillance)

Trial Identifier: D0817R00010
Sponsor: AstraZeneca
Start Date: February 2021
Primary Completion Date: August 2025
Study Completion Date: August 2025
Condition: Breast Cancer; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
South Korea Busan, South Korea
South Korea Daejeon, South Korea
South Korea Gunpo, South Korea
South Korea Hwaseong, South Korea
South Korea Ilsan, South Korea
South Korea Suwon, South Korea
South Korea Yongin, South Korea